Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

Paulfrench Jun. 24 at 9:31 AM

$NKTX I entered at $1.76, so the price should go down quite quickly! 🤣🤣🤣 In any case, yesterday's candle materializes a bearish VSA divergence (one more) it is the sign that buyers are gradually entering and testing the sellers, it is really the sign that we should see a bullish movement relatively quickly (I hope so in any case) 🤷‍♂️

1 · Reply

hopeteen Jun. 20 at 8:50 AM

$NKTX Any catalyst news in the near future?

1 · Reply

Paulfrench Jun. 17 at 8:43 AM

$NKTX Smells good guys! For me we have a clear signal of an upcoming bullish movement with possible support at $1.83 before taking off.

1 · Reply

BlakeCanyon50 Jun. 13 at 1:12 PM

$NKTX Tends to move on adverse market days.. Like Today…

0 · Reply

BlakeCanyon50 Jun. 11 at 5:07 PM

$NKTX Tick Tock Boys & Girls… 💥

0 · Reply

nightstocker15 Jun. 11 at 11:58 AM

$HSDT congrats to all that got in!! Gotta love profits to start the day! Don’t forget about $NKTX with over 5 bucks a share in cash on the books! Ripe for a huge bounce as well! 💪🥃🙌🤟🤝

0 · Reply

viking1111 Jun. 11 at 1:37 AM

$NKTX green days are always nice to see. We have been fooled though over and over after a run up then it pulls right back down. Looking at the chart I feel like I did months ago. This needs a strong pass and hold above 2.25 range, then head on up to the 200 ma. This hasn't been a fast mover, and that's ok if it can rebound. I sure want way more than the $2's.

0 · Reply

click_420 Jun. 10 at 3:43 PM

$NKTX starting a position here. How's the vibe

3 · Reply

anachartanalyst Jun. 10 at 3:02 PM

$NKTX https://anachart.com/wp-content/uploads/ana_temp/1749567703_soc-img.jpg

0 · Reply

McGinvests Jun. 10 at 2:56 PM

$CRDF $NKTX flying today in sync, what’s the news?

0 · Reply

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 5 weeks ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 5 weeks ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 3 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 3 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 3 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 3 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 3 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 4 months ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 7 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 7 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 8 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 9 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 10 months ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 11 months ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 11 months ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 11 months ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 11 months ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 1 year ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 1 year ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 1 year ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 2 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 2 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

Apr 17, 2023, 5:01 PM EDT - 2 years ago

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Nkarta Announces Departure of Chief Financial & Business Officer

Paulfrench Jun. 24 at 9:31 AM

1 · Reply

hopeteen Jun. 20 at 8:50 AM

$NKTX Any catalyst news in the near future?

1 · Reply

Paulfrench Jun. 17 at 8:43 AM

$NKTX Smells good guys! For me we have a clear signal of an upcoming bullish movement with possible support at $1.83 before taking off.

1 · Reply

BlakeCanyon50 Jun. 13 at 1:12 PM

$NKTX Tends to move on adverse market days.. Like Today…

0 · Reply

BlakeCanyon50 Jun. 11 at 5:07 PM

$NKTX Tick Tock Boys & Girls… 💥

0 · Reply

nightstocker15 Jun. 11 at 11:58 AM

0 · Reply

viking1111 Jun. 11 at 1:37 AM

0 · Reply

click_420 Jun. 10 at 3:43 PM

$NKTX starting a position here. How's the vibe

3 · Reply

anachartanalyst Jun. 10 at 3:02 PM

$NKTX https://anachart.com/wp-content/uploads/ana_temp/1749567703_soc-img.jpg

0 · Reply

McGinvests Jun. 10 at 2:56 PM

$CRDF $NKTX flying today in sync, what’s the news?

0 · Reply

McGinvests Jun. 10 at 2:54 PM

$NKTX

0 · Reply

nightstocker15 Jun. 10 at 2:36 PM

$KAPA $KLTO $NKTX you were told!! Selling Klto and loading more $NKTX!

0 · Reply

nightstocker15 Jun. 10 at 2:20 PM

$NKTX break 2 bucks and let’s run 💪🤟🥃

0 · Reply

Thestocktraderhubzee Jun. 10 at 2:15 PM

$NKTX Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $14

1 · Reply

vu_jade Jun. 10 at 1:54 PM

$NKTX swing bottom

0 · Reply

Gmebe Jun. 10 at 12:37 PM

$NKTX stock options galore for management. With minor refresh dates too I.e. hey vest in a years time or min 40% on that date then 60% in another year I'll assume at this points it's annual stock refreshes but also could be a "staff retention" method to see them through the 2h of this year and trial results.

0 · Reply

nightstocker15 Jun. 9 at 10:23 PM

$KLTO and $KAPA were great money makers today with huge moves! Bios heating up again, will $NKTX be next!?!? Over 5 bucks a share in cash on the books and can bounce in a hurry! 🥃

0 · Reply

EpiCRise98 Jun. 6 at 7:08 PM

$NKTX picking up 5k shares and going long

0 · Reply

nightstocker15 Jun. 6 at 3:35 PM

$NKTX stair stepping higher! Break through 2 next!

0 · Reply

McGinvests Jun. 5 at 4:18 PM

$QNCX $CRDF $NKTX $BTC These 4 stocks are my largest positions and will add over $1M to my trading accounts this year!!

1 · Reply

Lamatozore Jun. 5 at 10:12 AM

$NKTX this gonna be huge for us my brothers

0 · Reply

viking1111 Jun. 4 at 7:37 PM

$NKTX heading in the right direction. Keep on moving up.

0 · Reply

Market Cap	124.18M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	328,800
Avg Vol	534,936
Day's Range	N/A - N/A
Shares Out	70.96M
Stochastic %K	15%
Beta	0.72
Analysts	Strong Sell
Price Target	$13.00